In addition, driver genes, such as the EGFR mutation, were associated with a decreased TMB and impaired response to ICIs in patients with NSCLC.25,26 However, analysis of the TMB among patients with the EGFR mutation, EGFR wild type, or TP53 and ATM comutation with or without EGFR mutation found that when an EGFR mutation occurred with the TP53 and ATM comutation, patients still exhibited a high TMB level (eFigure 4C in the Supplement). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.